ALFA Finder| Revenue guidance | 39.2% → 43.1% Raised by 3.9 percentage points |
|---|---|
| Management target | Revenue 43.0% FY27 |
| Revenue growth | +62% YoY; +12% QoQ |
|---|---|
| Margins | EBITDA margin 27.5% vs 23.4% YoY; PAT margin 16.0% vs 13% |
| Demand visibility | Registrations LATAM, MENA, GCC, Malaysia; 750+ filings |
| Management confidence | Upbeat; 'solid execution' messaging |
Growth
Q2 revenue ₹181.2 Cr, +62% YoY; PAT ₹29.0 Cr, +106% YoY; EBITDA +96% YoY.
Outlook
FY27 revenue ₹720+ Cr (43%+). Hormone plant commercial production Q3 FY27; oncology expansion June 2027; Unit 7 by FY29.
Risks
Tax outgo rose 200% YoY to ₹13.2 Cr; debtor days still high at 178.
Investor Presentation filed with BSE, NSE: KPL. Summary written with AI assistance from the document.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,020.00
- Market cap
- ₹4,171 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 51.5×Sector 43.8×
- Promoter holding
- 54.86%+0.00% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Q2 FY27 Results: Net Profit ₹29 Cr, Up 105.7% YoY
Kwality Pharmaceuticals Ltd reported revenue from operations of ₹181.2 Cr (+63.1% YoY) and net profit of ₹29 Cr (+105.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹29 Cr · +105.7% YoY
Kwality Pharmaceuticals Board Meeting Date
Kwality Pharmaceuticals will hold a board meeting on November 12, 2026. The board will consider and approve unaudited financial results for the quarter and half-year ended September 2026.
Kwality Pharmaceuticals Business Update
Kwality Pharmaceuticals secured EU-GMP approval from Hungary for its Cephalosporin and Oncology facilities. This expands its EU-approved manufacturing footprint and positions it for global licensing opportunities.
Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Ltd filed its shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Kwality Pharmaceuticals Capacity Expansion
Kwality Pharmaceuticals acquired 4 acres adjacent to its Amritsar plant to build a fully automated facility with 10+ production lines. Completion is targeted by Q4 FY2028 with full operations by Q2 FY2029.
- Execution
- Completion by Q4 FY2028; full operations by Q2 FY2029
- manufacturing production lines (injectable + oral solid + ophthalmic)
- 10 production lines
Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.